25,618 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Purchased by CenterBook Partners LP

CenterBook Partners LP purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 25,618 shares of the medical research company's stock, valued at approximately $4,729,000. CenterBook Partners LP owned about 0.05% of Charles River Laboratories International as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Versant Capital Management Inc lifted its position in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after purchasing an additional 150 shares during the period. Pinnacle Bancorp Inc. raised its position in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in Charles River Laboratories International in the fourth quarter worth $48,000. Tortoise Investment Management LLC raised its holdings in Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after purchasing an additional 115 shares in the last quarter. Finally, Huntington National Bank boosted its holdings in shares of Charles River Laboratories International by 120.6% during the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company's stock valued at $55,000 after buying an additional 164 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Insider Activity at Charles River Laboratories International

In other news, COO Birgit Girshick bought 1,514 shares of the firm's stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James C. Foster purchased 6,075 shares of the company's stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Stock Performance

CRL traded up $5.83 during mid-day trading on Monday, reaching $105.58. 1,415,709 shares of the company traded hands, compared to its average volume of 861,054. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The company's fifty day moving average price is $156.71 and its 200-day moving average price is $176.86. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $5.19 billion, a P/E ratio of 703.87, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.46 EPS. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. cut their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. Morgan Stanley lowered their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Finally, Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price target for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and a consensus target price of $182.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).